Invectys : lutter contre toutes les formes de cancers Avec 382 000 nouveaux cas et 157 400 décès par an, le cancer demeure une priorité absolue en matière de…
Pipeline Depth Underpinned by Multiple Indications and Platforms Invectys Inc. develops a full range of innovative and very promising immunotherapeutic oncology…
Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. …
To help us orient our long-term decisions and strategy, we rely on an experienced and dependable board of seasoned industry professionnals, investors and health…
Monoclonal antibodies targeting checkpoint inhibitors are hugely important immunotherapy molecules for the treatment cancers…
Invectys’ Scientific and Clinical Board is composed of globally recognized top specialists and key opinion leaders: Professor Maurizio Zanetti, M.D. A professor…
The main product of Invectys is a DNA vaccine targeting Telomerase…
Invectys Inc. is led by a team of experienced industry professionals, combining vision, scientific knowledge and management skills. Praveen Tyle, Ph.D., President…
